How much does an inpatient C. diff infection cost?

The healthcare industry is well aware that healthcare-associated infections are a significant financial burden to the country’s overall healthcare costs, at the sum of several billion dollars each year.

Advertisement

Researchers conducted a study at Barnes-Jewish Hospital in St. Louis to determine the attributable inpatient costs of recurrent Clostridium difficile infections. The results were reported in Infection Control and Hospital Epidemiology.

Researchers studied the medical records of nearly 4,000 adult patients who developed an initial C. difficile infection from 2003 through 2009 and analyzed the average cost for those who developed recurrent infections.

They found the average cost of a recurrent C. difficile infection was $11,361.

Researchers suggest better strategies are needed to predict and prevent C. difficile recurrences.

More articles on HAIs:

Hospital infection control thrust into public eye, courtesy of Ebola
Sources of bloodstream infections differ in hospital-, community-onset cases
Tennessee dialysis clinic loses license over infection control violations

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

When nurses help build the AI, adoption follows: Lessons from 3 health systems

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Amy McCarthy, DNP, RNC-MNN, NE-BC, CENP, Hippocratic AIBeth Reimschissel, PhD, RN, CNL, Memorial HermannAllison Schlinkert, MSN, RN, NPD-BC, Cincinnati Children'sScott Estep, MBOE, BSN, RN, CSSBB, OhioHealth System

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.